It has a direct relaxant effect on the smooth muscles of the respiratory tract, which is partly due to the release of endogenous adrenaline and norepinephrine; as a purine receptor blocker, it can counteract the contractile effect of adenine and other substances on the respiratory tract; it enhances the contractility of the diaphragm and improves respiratory function.

It can directly stimulate adrenaline receptors, and can also indirectly stimulate receptors by prompting adrenergic nerve endings to release norepinephrine, dilate bronchi, and constrict local blood vessels to eliminate congestion and swelling of the nasopharyngeal mucosa and relieve symptoms of nasal congestion; strengthen myocardial contractility, enhance cardiac output, and ensure sufficient venous return to the heart; it has a strong effect of stimulating the central nervous system.

Theophylline has a direct relaxant effect on the smooth muscle of the respiratory tract, and its effect is partly due to the release of endogenous adrenaline and norepinephrine. In addition, theophylline is a purine receptor blocker, which can counteract the contraction of adenine and other substances on the respiratory tract. Theophylline can enhance the contraction of the diaphragm, especially when the diaphragm is weak, so it is beneficial to improve respiratory function. Methylephedrine hydrochloride can directly stimulate adrenaline receptors, and can also indirectly stimulate adrenaline receptors by prompting adrenergic nerve endings to release norepinephrine, and has an stimulating effect on both alpha and beta receptors. It can dilate the bronchi and contract local blood vessels to eliminate congestion and swelling of the nasopharyngeal mucosa, relieve nasal congestion symptoms, and has a longer duration of action; strengthen myocardial contractility, increase cardiac output, and make venous return to the heart sufficient; it has a stronger central nervous system excitation effect than adrenaline.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It also has good effects on Chlamydia trachomatis, Mycoplasma, Legionella, and antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA gyrase, inhibiting DNA synthesis and replication, leading to bacterial death.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It also has good effects on Chlamydia trachomatis, Mycoplasma, Legionella, and antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA gyrase, inhibiting DNA synthesis and replication, leading to bacterial death.

Has anti-inflammatory and anti-allergic effects

It has the effects of promoting local circulation and mildly anti-inflammatory, analgesic and antipruritic

It has the effects of promoting local circulation and mildly anti-inflammatory, analgesic and antipruritic

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the transfer of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.